CVS Caremark (NYSE:CVS) reported a mixed Q1, although the fundamentals may have been stronger than the headlines indicated. After all, adjusted EPS grew by 22.5% to $1.02, while revenue increased 6.3% to $32.7 billion.

And while the Pharmacy Services Segment (the PBM portion of the business) led the charge with a 10.3% bump in revenue, retail pharmacy revenue still increased by 2.7%, driven by a same store sales increase of 1.4%. And MinuteClinic revenue climbed 11%. This all happened despite some pretty nasty winter weather which affected foot traffic across the retail space.

The company maintained its guidance, for 5.3% to 6.5% revenue growth and 10% to 14% growth in adjusted EPS, which highlights the company's continued growth prospects.

There was a lot to be excited about in the earnings. In the video below, Motley Fool health care analysts Michael Douglass and David Williamson dig in with a quick 3 minute clinic on CVS' earnings.

David Williamson has no position in any stocks mentioned, and neither does Michael Douglass. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.